Drug resistance in leishmaniasis.
Drug resistance in leishmaniasis.
复制标题
DOI：
10.4103/0974-777x.62887
复制
发表时间：
2010-05
影响因子：
1.6
通讯作者：
Sundar S
中科院分区：
文献类型：
--
作者：
Chakravarty J;Sundar S
利什曼病的治疗选择是有限的，远远不能令人满意。60多年来，利什曼病的治疗一直围绕五价锑（Sbv）。广泛的滥用导致北比哈尔邦高流行地区出现了Sbv耐药性。其他反利什曼主义者也可能面临同样的命运，特别是在人类周期中。HIV/内脏利什曼病（VL）合并感染的患者是另一个潜在的耐药源的出现。目前，没有可用的耐药分子标记，监测分离株耐药的唯一可靠方法是技术要求高的体外无鞭毛体-巨噬细胞模型。由于治疗利什曼病药物的有效性有限，因此必须对药物使用和反应进行有效监测，以防止耐药性的传播。应认真考虑同时或顺序组合的方案，以限制耐药性的出现。
The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sbv). Widespread misuse has led to the emergence of Sbv resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.